Harvard Pilgrim Health Care
http://www.harvardpilgrim.org/public/home
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Harvard Pilgrim Health Care
Alnylam Turns To Value-Based Pricing Again For Oxlumo
Bookmark
-
Analysis
As with its first two approved RNAi therapies, Alnylam will negotiate value-based agreements with payers, but for Oxlumo, approved in pediatric patients, it will offer a patient need adjustment.
Company Information
Advertisement
Advertisement